The claims and ensuing settlement revolve around Biohaven’s CGRP receptor antagonist Nurtec ODT, which is cleared to both treat and prevent migraines in adults. The drug, which was the crown ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback